Riociguat 13CD3
| Product Name | Riociguat 13CD3 |
|---|---|
| Alternate Names | Riociguat Stable Isotopes, Stable Isotopes of Riociguat |
| CAT No. | CS-O-15618 |
| CAS No. | 625115-55-1(Unlabeled) |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 426.43 g/mol |
| Mol. For. | C₁₉¹³CH₁₆D₃FN₈O₂ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Riociguat |
| Purity | 95% |
| Smileys | FC1=C(C=CC=C1)CN2N=C(C3=NC(N)=C(N([13C]([2H])([2H])[2H])C(OC)=O)C(N)=N3)C4=CC=CN=C24 |
| Canonical Smiles | CN(C1=C(N=C(N=C1N)C2=NN(C3=C2C=CC=N3)CC4=CC=CC=C4F)N)C(=O)OC |
| InchIKey | WXXSNCNJFUAIDG-UHFFFAOYSA-N |
| Inchl | InChI=1S/C20H19FN8O2/c1-28(20(30)31-2)15-16(22)25-18(26-17(15)23)14-12-7-5-9-24-19(12)29(27-14)10-11-6-3-4-8-13(11)21/h3-9H,10H2,1-2H3,(H4,22,23,25,26) |
| IUPAC | methyl N-[4,6-diamino-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]-N-methylcarbamate |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Riociguat 13CD3 is a medication that is primarily used to treat pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). It is also used to treat other conditions such as Raynaud's phenomenon, a disorder that affects blood flow to the fingers and toes.
The chemical name of Riociguat 13CD3 is Methyl 4,6-diamino-2-(1-methoxy-1-methylethyl)-5-{[4-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-yl]amino}pyrimidine-7-carboxylate, and its molecular formula is C20H19N7O3. Riociguat 13CD3 belongs to a class of drugs called soluble guanylate cyclase (sGC) stimulators. It works by increasing the production of cyclic guanosine monophosphate (cGMP), which promotes the relaxation of blood vessels and improves blood flow.
Riociguat 13CD3 is available in the form of tablets for oral administration. The recommended dosage and duration of treatment may vary depending on the condition being treated, the patient's age, and overall health. Riociguat 13CD3 should be taken as directed by a healthcare provider and should not be stopped or changed without medical advice.
Like all medications, Riociguat 13CD3 may cause side effects such as headache, dizziness, nausea, and diarrhea. Rare but serious side effects may include bleeding, low blood pressure, and liver damage. It is important to inform a healthcare provider of any unusual symptoms or changes in health while taking Riociguat 13CD3.
Get an Instant Quote
Related Compounds
Riociguat-d3 | Riociguat-d6 |